Careers

Learn more

Qualified professionals

Learn more

Trainee & intern programmes

Learn more

Offices

New York

Learn more

San Francisco

Learn more
A&L Goodbody logo
Q1 2026 update

Corporate and M&A

Q1 2026 update

This update sets out the key market, legal and regulatory, and tax developments during Q1 2026 that are applicable to US-listed Irish companies.

Fri 27 Mar 2026

10 min read

Market update

M&A – Resilient amid uncertainty

Despite continued global geopolitical and macroeconomic volatility, M&A activity in Q1 involving Irish businesses remained resilient. Alkermes closed its US$2.37bn acquisition of Avadel Pharmaceuticals, Willis Towers Watson completed its US$1.3bn acquisition of Newfront and bolt-on activity continues apace across tech/AI, life sciences, financial services and energy/infrastructure. 

Separations – Unlocking value

Corporate separations remain a dominant theme as companies work to simplify their business operations and unlock value by shedding non-core assets and refining their capital allocation strategies. Irish law offers a high degree of flexibility to facilitate spin-offs, split-offs and other separation transactions, supporting both in-bound and out-bound structures (e.g. separations into a new US company). Notable recent activity has included:

Fundraising – Debt over Equity: Not unexpectedly given market volatility, equity fundraising remained muted. Where issuers have urgent funding needs, there has been a shift toward alternative fundraising options, including through private placements/ private investments in public equity (PIPEs) and standby equity facilities with cornerstone investors.

Prior to the most recent escalation of hostilities in the Middle East, the debt markets were more active with issuers taking advantage of financing conditions to refinance and reprice debt and in some cases, take on new debt to fund transformational acquisitions. Alongside this, we saw a continued focus on balance sheet optimisation, including selective deleveraging through repayments and, where appropriate, equitisation of existing debt.

Proxy season and shareholder activism – Steady start, continued preparedness

Proxy season has commenced but there have been no major developments or any unusual shareholder proposals to date. Following changes in ISS guidance in 2023, it has become relatively standard for Irish incorporated, US‑listed companies to seek annual renewal of their allotment and pre‑emption authorities capped at 20% (with only a small number pursuing broader authorities where this can be specifically justified to shareholders based on capital raising needs).

While there have been no public activist campaigns involving US listed, Irish companies to date in 2026, we expect activist shareholder activity will continue. Companies should remain vigilant and focus on preparedness, including regularly reviewing defence strategies, and in some cases, considering the adoption of a shareholder rights plan.

Irish tax developments

Participation exemption for foreign dividends: Following its introduction last year, Ireland’s participation exemption for foreign dividends has been substantially amended with effect from 1 January 2026 to ensure the regime functions as intended for groups with global structures. Updates include:

Interest regime reform – Department of Finance Consultation: The Irish government published its Phase One Feedback Statement on potential changes to Ireland’s long-standing interest taxation regime, including potential adoption of a profit-motive-based test, improved alignment in the treatment of different categories of interest income and expense, and broader updates to ensure the regime remains resilient, competitive and aligned with international tax commitments. Stakeholder responses to the first public consultation highlighted the complexity of the existing rules and the need for more detailed consideration before introducing legislative reform. Reflecting this, the government’s action plan provides for a phased approach to reform, with Phase One addressing priority issues identified by stakeholders with further changes to be considered in subsequent phases. The consultation on the Feedback Statement closed on 16 January 2026, and the Department is now assessing submissions to inform the next stage of the reform process. A&L Goodbody’s response to the Public Consultation on the Tax Treatment of Interest can be found here.

Research and Development Tax Credit and Innovation Compass: The Irish government continues to enhance its R&D tax credit regime by:

Tax Appeals Commission – Proposed hearing reforms: The Irish government continues to pursue legislation towards a more transparent tax appeals process which would result in all Tax Appeals Commission hearings being held in public by default, with determinations published in full with only a limited ability to seek private hearings and redacted determinations. This would represent a significant departure from the current practice under which the vast majority of cases are heard in private. Further developments are expected later this year.

Market capitalisation stamp duty exemption: To support smaller publicly listed companies and increase the competitiveness of Ireland’s capital markets, an exemption from the 1% charge to Irish stamp duty for transfers of shares in listed companies with a market capitalisation below €1bn has been introduced effective from 1 January 2026 through to 31 December 2030. To qualify, the shares must be admitted to trading on a “relevant market”, and a notification to Irish Revenue is required. Irish Revenue are maintaining a published list of all valid notifications received. As of 4 March 2026, 21 companies have made a valid notification to Irish Revenue however, as expected, uptake by US-listed companies has been limited given the existing stamp duty exemption for shares traded through DTC.

Date published: 30 March 2026

Key Contacts